Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
CD4+CD25+ regulatory T cells (T reg cells) play a key role in controlling autoimmunity and inflammation. Therefore, therapeutic agents that are capable of elevating numbers or increasing effector functions of this T cell subset are highly desirable. In a previous report we showed that a superagonistic monoclonal antibody specific for rat CD28 (JJ316) expands and activates T reg cells in vivo and upon short-term in vitro culture. Here we demonstrate that application of very low dosages of the CD28 superagonist into normal Lewis rats is sufficient to induce T reg cell expansion in vivo without the generalized lymphocytosis observed with high dosages of JJ316. Single i.v. administration of a low dose of the CD28 superagonist into Dark Agouti (DA) rats or Lewis rats that suffered from experimental autoimmune encephalomyelitis (EAE) proved to be highly and equally efficacious as high-dose treatment. Finally, we show that T reg cells that were isolated from CD28-treated animals displayed enhanced suppressive activity toward myelin basic protein–specific T cells in vitro, and, upon adoptive transfer, protected recipients from EAE. Our data indicate that this class of CD28-specific monoclonal antibodies targets CD4+CD25+ T reg cells and provides a novel means for the effective treatment of multiple sclerosis and other autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The antibody had specificity for the C’’D loop of the CD28 glycoprotein and had the unique capacity to activate T-cells solely through CD28 (signal 2) without the usual ligation of the T-cell receptor (signal 1) [27].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading, as of today, to 25 original publications describing efficacious therapy in a large number of rat and mouse disease models”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“similar reagents had shown efficacy in rodent models for treating autoimmune disease (2-4).”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [2]
In the citing paper
“Titration of the CD28SA in vivo revealed that at high doses, both conventional T cells and Treg cells were activated, whereas at low doses, only Treg cells expanded measurably, providing a window for selective targeting of that subset [3].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“” The cytokines IL-4 and IL-13 were responsible for this alternative activation of macrophages that led to the production of antiinflammatory cytokines by the macrophage (42).”
BackgroundPark, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 13×
“Experiments with human T reg cell clones further showed that expression of CTLA-4 positively correlated with their suppressive capacity (22, 23).”
BackgroundInfluentialRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Cited by
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Gold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017
“, 2003) and can directly induce regulatory T cells, which suppress acute and chronic EAE, even upon passive transfer (Beyersdorf et al., 2005).”
BackgroundSelf-citationDietary fatty acids directly impact central nervous system autoimmunity via the small intestine
Haghikia, A., Jörg, S., Duscha, A., Berg, J., Manzel, A., Waschbisch, A., Hammer, A., Lee, D.-H., May, C., Wilck, N., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.007 · Cited by 927
“, via superagonistic anti-CD28 antibodies, has been considered worthwhile (Beyersdorf et al., 2005) but not practically feasible outside of controlled experimental conditions (Hünig, 2012).”
Self-citationImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Austin, P. J., & Moalem-Taylor, G. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.08.013 · Cited by 607
“This approach has been validated in several models of auto-immunity (Beyersdorf et al., 2005; Kitazawa et al., 2009), although clinical trials with the Treg activator, TGN1412, led to severe adverse effects (Suntharalingam et al.”
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
Riley, J. L., June, C. H., & Blazar, B. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.006 · Cited by 412
“Preclinical data in animal models demonstrated that this Ab preferentially activated Treg cells, and it was thus postulated that TGN1412 could restore tolerance and enable transplants (Beyersdorf et al., 2005; Lin and Hunig, 2003).”
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
“Preclinical studies in rats with a CD28-superagonist antibody showed that treatment expanded the numbers of Treg cells in vivo and that these Tregs showed enhanced suppressive functions in vitro and in vivo (271).”
BackgroundImbalance of regulatory T cells in human autoimmune diseases
Dejaco, C., Duftner, C., Grubeck‐Loebenstein, B., & Schirmer, M. (2006) · Immunology · doi:10.1111/j.1365-2567.2005.02317.x · Cited by 368
Transient regulatory T-cells: A state attained by all activated human T-cells
Pillai, V., Ortega, S. B., Wang, C. K., & Karandikar, N. J. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.10.014 · Cited by 339
“Prior studies has shown increased Treg induction by this agent [48;49].”
BackgroundRegulatory T cells ameliorate cardiac remodeling after myocardial infarction
Tang, T.-T., Yuan, J., Zhu, Z.-F., Zhang, W.-C., Xiao, H., Xia, N., Yan, X.-X., Nie, S.-F., Liu, J., Zhou, S.-F., et al. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-011-0232-6 · Cited by 318
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
“anti-CD28 monoclonal antibody in Lewis rats results in Treg cell expansion and reduction in EAE disease severity [48].”
BackgroundEastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
“…© 2010 The British Pharmacological Society CD28 superagonists orthologous to TGN1412 stimulated the release of anti-inflammatory cytokines and the expansion of regulatory T-cells believed to counter autoimmune responses (RodríguezPalmero et al., 1999; Lin and Hünig, 2003; Beyersdorf et al., 2005).”
BackgroundThe role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
Sansom, D. M., & Walker, L. S. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00419.x · Cited by 293
“In support of this concept, superagonistic anti-CD28 antibodies, which probably cause augmented CD28 signaling, are particularly effective at supporting Treg expansion in vivo (138, 139).”
BackgroundThe role of regulatory T cells in multiple sclerosis
Zozulya, A. L., & Wiendl, H. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0832 · Cited by 240
“Animals treated with a CD28 superagonist that preferentially promotes TREG-cell expansion MOG-induced EAE in C57Bl/6 mice Prevention of acute and chronic EAE CD28 superagonist acts via expansion of TREG cells; active at very low doses; potential for therapeutic use Beyersdorf et al. (2005)42”
BackgroundBour‐Jordan, H., & Bluestone, J. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00775.x · Cited by 223
“The authors proposed that it could be related to the autoreactive repertoire of Tregs (77).”
BackgroundBiologic therapies in rheumatology: lessons learned, future directions
Strand, V., Kimberly, R., & Isaacs, J. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2196 · Cited by 216
“In preclinical rodent experiments using homologous mAbs, FcγR-dependent crosslinking of a precise epitope on the CD28 molecule resulted in a selective expansion of regulatory T cells, with beneficial effects on autoimmunity and without apparent side effect”
BackgroundRegulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis
Zaiss, M. M., Frey, B., Hess, A., Zwerina, J., Luther, J., Nimmerjahn, F., Engelke, K., Kollias, G., Hünig, T., Schett, G., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903841 · Cited by 205
“It was demonstrated that CD28 SA was capable of expanding functional CD4CD25 Treg cells (34), which were effective in the treatment of experimental autoimmune encephalomyelitis (35).”
BackgroundT-cell costimulation–biology, therapeutic potential, and challenges.
Sharpe, A. H., & Abbas, A. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068087 · Cited by 206
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194
Regulatory T Cells and Human Disease
Cools, N., Ponsaerts, P., Van Tendeloo, V. F. I., & Berneman, Z. N. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/89195 · Cited by 190
“In support of this concept, superagonistic anti-CD28 antibodies, which probably cause augmented CD28 signaling, are particularly effective at supporting Treg expansion in vivo [116, 117].”
BackgroundElinav, E., Waks, T., & Eshhar, Z. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.060 · Cited by 180
Molecular mechanisms linking neuroinflammation and neurodegeneration in MS
Ellwardt, E., & Zipp, F. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.02.006 · Cited by 175
“Also, regulatory T-cell stimulants such as the CD28 superagonist (JJ316) attenuated the disease course in EAE (Beyersdorf et al., 2005; Tischner et al., 2006).”
BackgroundAustin, P. J., Kim, C. F., Perera, C. J., & Moalem-Taylor, G. (2012) · Pain · doi:10.1016/j.pain.2012.06.005 · Cited by 180
“Previous reports have demonstrated that application of low-dose CD28SupA into normal Lewis rats induces expansion of Treg cells in vivo [6].”
BackgroundResultInfluentialREVIEW ARTICLE: Regulatory T Cells and Their Role in Pregnancy
Leber, A., Teles, A., & Zenclussen, A. C. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00821.x · Cited by 162
CD28 co-stimulation in T-cell homeostasis: a recent perspective
Hünig, T., Beyersdorf, N., & Kerkau, T. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61647 · Cited by 190
“In line with this conclusion, Treg cells, which, in contrast to all conventional T-cells not undergoing an immune response, are constantly stimulated by recognition of cognate (self-) antigen and hence display a higher level of phosphorylation in their TCR signal transduction machinery,(93) and are activated by lower…”
Self-citationSharma, S., Chopra, K., Kulkarni, S. K., & Agrewala, J. N. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03257.x · Cited by 150
Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells.
Yi, H., Yu, Z., Jiang, L., Zheng, J., & Zhao, Y. L. (2006) · PubMed · Cited by 162
Wang, J., Takeuchi, H., Sonobe, Y., Jin, S., Mizuno, T., Miyakawa, S., Fujiwara, M., Nakamura, Y., Kato, T., Muramatsu, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709592105 · Cited by 129
Na, S., Mracsko, E. Z., Liesz, A., Hünig, T., & Veltkamp, R. C. (2014) · Stroke · doi:10.1161/strokeaha.114.007756 · Cited by 128
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine
Haghikia, A., Jörg, S., Duscha, A., Berg, J., Manzel, A., Waschbisch, A., Hammer, A., Lee, D.-H., May, C., Wilck, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.006 · Cited by 122
Self-citationT Regulatory Cells in Bone Remodelling
Bozec, A., & Zaiss, M. M. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0356-1 · Cited by 110
Jhunjhunwala, S., Balmert, S. C., Raimondi, G., Dons, E. M., Nichols, E. E., Thomson, A. W., & Little, S. R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.013 · Cited by 104
“Various antibodies (Abs), such as anti-IL-2 monoclonal (m) Ab [20], superagonistic anti-CD28 mAb [21], and agonistic anti-CD4 mAb [22], have been used in the past to increase in vivo Treg numbers.”
Fcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
“In mice, CD28 super-agonistic antibodies promoted the expansion of T reg cells without affecting T eff cells, with potential benefits for autoimmunity 175,176 and treatment of B cell chronic lymphocytic leukaemia 177 .”
Keeler, G. D., Kumar, S., Palaschak, B., Silverberg, E. L., Markusic, D. M., Jones, N. T., & Hoffman, B. E. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.001 · Cited by 97
“Although MOG protein accounts for only 0.05%–0.1% of total myelin proteins, it is reported to induce a more potent T cell response than other myelin antigens in patients with MS.18,19 To complicate matters, a loss of immune tolerance because of deficits in either Treg numbers or their function has been observed in aut…”
BackgroundMethodInfluentialTabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Targeting Treg signaling for the treatment of autoimmune diseases
Spence, A., Klementowicz, J. E., Bluestone, J. A., & Tang, Q. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.09.002 · Cited by 92
“It is worth mentioning that a form of agonist anti-CD28 was shown to selectively increase Tregs and prevent experimental allergic encephalitis, a model of multiple sclerosis (MS) [67].”
BackgroundCFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes
Steines, B., Dickey, D. D., Bergen, J., Excoffon, K. J. D. A., Weinstein, J. R., Li, X., Yan, Z., Alaiwa, M. H. A., Shah, V. S., Bouzek, D. C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88728 · Cited by 92
“For example, an immunomodulatory humanized agonistic anti-CD28 monoclonal antibody that was developed for multiple sclerosis, rheumatoid arthritis, and certain cancers was deemed to be safe in animal models (52).”
BackgroundLoisel, S., Ohresser, M. C. P., Pallardy, M. J., Daydé, D., Berthou, C., Cartron, G., & Watier, H. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.11.010 · Cited by 98
Korporal, M., Haas, J., Balint, B., Fritzsching, B., Schwarz, A., Moeller, S., Fritz, B., Suri‐Payer, E., & Wildemann, B. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1434 · Cited by 90
Liu, J., Gong, N., Huang, X., Reynolds, A. D., Mosley, R. L., & Gendelman, H. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803330 · Cited by 89
“This is evident from an abundant amount of evidence demonstrating that Treg modulate inflammatory responses in graft-vs-host-disease (61) and autoimmune disorders including arthritis (62), diabetes (63), and experimental autoimmune encephalitis (64, 65).”
BackgroundCostimulatory pathways in transplantation
Pilat, N., Sayegh, M. H., & Wekerle, T. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.04.002 · Cited by 93
“In rodents, in sharp contrast, superagonistic anti-CD28 therapy had not been associated with massive release of pro-inflammatory cytokines [57], presumably because activation and expansion of Tregs effectively suppressed the inflammatory response [62].”
BackgroundEnhancement of antigen-specific Treg vaccination in vivo
Daniel, C., Wennhold, K., Kim, H. J., & von Boehmer, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007422107 · Cited by 89
“Cells with this phenotype could be conceivably counterproductive to tolerance induction and given recent results on the activation of T cells by an agent (anti-CD28 superagonist antibodies) supposed to expand Tregs only (31) it appeared mandatory to analyze whether the injection of IL-2/IL-2 IL-2/IL2ab complexes would…”
ResultHarper, J., Adams, K. J., Bossi, G., Wright, D. E., Stacey, A. R., Bedke, N., Martinez-Hague, R., Blat, D., Humbert, L., Buchanan, H., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0205491 · Cited by 84
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist
Khan, D. A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.013 · Cited by 91
Cyclic AMP underpins suppression by regulatory T cells
Bodor, J., Bopp, T., Vaeth, M., Klein, M., Serfling, E., Hünig, T., Becker, C., Schild, H., & Schmitt, E. (2012) · European Journal of Immunology · doi:10.1002/eji.201141578 · Cited by 88
Legrand, N., Cupedo, T., van Lent, A. U., Ebeli, M. J., Weijer, K., Hanke, T., & Spits, H. (2006) · Blood · doi:10.1182/blood-2006-01-0190 · Cited by 82
Self-citationTischner, D. (2006) · Brain · doi:10.1093/brain/awl213 · Cited by 82
“…expands T reg cells (Lin and Hünig, 2003) and this is believed to underlie its efficacy in the treatment of rodent models of autoimmune diseases such as EAE (Beyersdorf et al., 2005), experimental autoimmune neuritis (Schmidt et al., 2003a) and rheumatoid arthritis (Rodriguez-Palmero et al., 2006).”
InfluentialRegulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia
Brea, D., Agulla, J., Rodríguez‐Yáñez, M., Barral, D., Ramos‐Cabrer, P., Campos, F., Almeida, Á., Dávalos, A., & Castillo, J. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12304 · Cited by 81
“injection of 1 ml of PBS (n = 8), or 500 mg of anti-CD28 mAb [24] (clone JJ316; BD Biosciences) in 1 ml of PBS (n = 8), 4 days before the ischaemia.”
BackgroundMethodRapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
Gogishvili, T., Langenhorst, D., Lühder, F., Elias, F., Elflein, K., Dennehy, K. M., Gold, R., & Hünig, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004643 · Cited by 79
“Our present results using a mouse-anti mouse CD28SA confirm the preferential expansion and activation of Treg over conventional CD4 T-cells initially reported in rats [17,19], and suggest a”
ResultInfluentialSelf-citationSignaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundThe calm after the cytokine storm: lessons from the TGN1412 trial
St. Clair, E. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35382 · Cited by 79
Regulatory T cells in experimental autoimmune disease
Suri‐Payer, E., & Fritzsching, B. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0021-8 · Cited by 84
After TGN1412: Recent developments in cytokine release assays
Stebbings, R., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711783 · Cited by 73
“…and adjuvant arthritis, treatment with anti-CD28 mAbs orthologous to TGN1412 stimulated the release of antiinflammatory cytokines and the expansion of regulatory T-cells believed to counter autoimmune responses (Rodríguez-Palmero et al., 1999; Lin and Hünig, 2003; Beyersdorf et al., 2005).”
BackgroundMagee, C. N., Boenisch, O., & Najafian, N. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04180.x · Cited by 86
“Use of a superagonistic anti-CD28 mAb in rodent models was shown to preferentially activate and expand functional Tregs both in vitro and in vivo (105,106); unfortunately, attempts to translate this therapy into clinical use were disastrous: in Phase I clinical trials, six healthy volunteers developed a massive cytoki…”
BackgroundCoquerelle, C., Oldenhove, G., Acolty, V, Denoeud, J., Vansanten, G., Verdebout, J.-M., Mellor, A., Bluestone, J. A., & Moser, M. (2009) · Gut · doi:10.1136/gut.2008.162842 · Cited by 71
“Consistent with this notion, low-dose CD28 superagonist treatment appears selectively to increase the pool of Tregs in vivo.”
BackgroundFOXP3+ T regulatory cells in lesions of oral lichen planus correlated with disease activity
Tao, X., Xia, J., Chen, X.-B., Wang, H. H., Dai, Y.-H., Rhodus, N., & Cheng, B. (2009) · Oral Diseases · doi:10.1111/j.1601-0825.2009.01608.x · Cited by 71
Safety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
Hemmer, B., & Hartung, H. (2007) · Annals of Neurology · doi:10.1002/ana.21289 · Cited by 70
“Similarly, an antiCD28 antibody (TGN1412), which ameliorated EAE by expanding regulatory T cells, was recently tested in a phase I trial in healthy control subjects.(106) This agent, designed for the treatment of autoimmune diseases including MS, had devastating acute and possibly chronic side effects.”
BackgroundF lt3 ligand expands CD 4+ F ox P 3+ regulatory T cells in human subjects
Klein, O., Ebert, L. M., Zanker, D. J., Woods, K., Tan, B. S., Fucikova, J. P., Behren, A., Davis, I. D., Maraskovsky, E., Chen, W., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242603 · Cited by 67
Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers
Verreycken, J., Baeten, P., & Broux, B. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2153534 · Cited by 65
“However, in a preclinical murine model for MS, called experimental autoimmune encephalomyelitis (EAE), Tregs were found to become unstable after entry in the CNS due to the downregulation of FOXP3 expression, leading to a reduced suppressive capacity.72,73 In a different study, myelin-specific Tregs accumulate in the…”
BackgroundInfluentialTherapeutic T-cell manipulation in rheumatoid arthritis: past, present and future
Isaacs, J. D. (2008) · Rheumatology · doi:10.1093/rheumatology/ken163 · Cited by 60
TGN1412—a regulator's perspective
Schneider, C. K., Kalinke, U., & Löwer, J. (2006) · Nature Biotechnology · doi:10.1038/nbt0506-493 · Cited by 64
Signals and pathways controlling regulatory T cells
Huynh, A., Zhang, R., & Turka, L. A. (2014) · Immunological Reviews · doi:10.1111/imr.12148 · Cited by 66
Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release
Eastwood, D., Bird, C., Dilger, P., Hockley, J., Findlay, L., Poole, S., Thorpe, S. J., Wadhwa, M., Thorpe, R., & Stebbings, R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12165 · Cited by 58
CD28 superagonists: Mode of action and therapeutic potential
Hünig, T., & Dennehy, K. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.012 · Cited by 63
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies
Hünig, T. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)95004-x · Cited by 57
Hombach, A. A., Kofler, D., Hombach, A., Rappl, G., & Abken, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7924 · Cited by 56
“Treg cells in a mouse model in vivo (10).”
Backgroundvan den Brandt, J., Fischer, H. J., Walter, L., Hünig, T., Klöting, I., & Reichardt, H. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000462 · Cited by 54
“Adoptive cell transfer represents a promising strategy to interfere with autoimmune and other inflammatory diseases (35, 40).”
BackgroundMethodA more selective costimulatory blockade of the CD28-B7 pathway
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01176.x · Cited by 54
CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 52
“Key words: Alloreactivity, autoimmunity, immune tolerance, immunomodulation, kidney transplantation, regulatory T cells Abbreviations: APCs, antigen-presenting cells; B7, CD80/86 molecules; CNI, Calcineurin inhibitors; IDO, indoleamine 2,3-dioxigenase; DST, donor-specific blood transfusion; EAE, experimental autoimmun…”
BackgroundRoles of CD4+CD25high FOXP3+ Tregs in lymphomas and tumors are complex
Ke, X., Wang, J., Li, L., Chen, I.-L., Wang, H., & Yang, X. (2008) · Frontiers in bioscience · doi:10.2741/2986 · Cited by 55
“In addition, the use of super-agonist antiCD28 antibodies in vivo results in the rapid expansion of Tregs (77), and rodent experimental data suggest that they may be useful in the treatment of autoimmune diseases (78) and graft-versus-host disease (75, 79).”
BackgroundLi, R., Li, H., Yang, X., Hu, H., Liu, P., & Liu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970508 · Cited by 57
“Selectively targeting Tregs in normal Lewis rats with very low doses of the CD28 superagonist was shown to be sufficient to induce Treg cell proliferation in vivo and enable the effective treatment of EAE (47).”
BackgroundThe rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46
TGN1412: Time to Change the Paradigm for the Testing of New Pharmaceuticals
Bhogal, N., & Combes, R. (2006) · Alternatives to Laboratory Animals · doi:10.1177/026119290603400204 · Cited by 45
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
Linker, R. A., & Lee, D.-H. (2009) · Experimental & Translational Stroke Medicine · doi:10.1186/2040-7378-1-5 · Cited by 43
Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis
Keino, H., Takeuchi, M., Usui, Y., Hattori, T., Yamakawa, N., Kezuka, T., Sakai, J., & Usui, M. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099192 · Cited by 48
Animal models of multiple sclerosis
Wekerle, H., & Kurschus, F. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.11.004 · Cited by 7
Self-tolerance in multiple sclerosis
Gonsette, R. E. (2012) · Acta Neurologica Belgica · doi:10.1007/s13760-012-0061-x · Cited by 41
“Interestingly, transplantation of Aire-encoding bone marrow cells in mice attenuates the development of MOG-induced experimental autoimmune encephalomyelitis (EAE) [5].”
BackgroundInfluentialBartholomaeus, P., Semmler, L. Y., Bukur, T., Boisguerin, V., Römer, P. S., Tabares, P., Chuvpilo, S., Tyrsin, D. Y., Matskevich, A., Hengel, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302461 · Cited by 40
Self-citationBadr, M., McFleder, R. L., Wu, J., Knörr, S., Koprich, J. B., Hünig, T., Brotchie, J. M., Volkmann, J., Lutz, M. B., & Ip, C. W. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02685-7 · Cited by 41
“In animal models of multiple sclerosis and stroke, CD28SA-triggered Treg were shown to suppress inflammation in the periphery and to migrate to the CNS where they exert their effect by turning the environment from pro-inflammatory to anti-inflammatory and neuroprotective [34, 35].”
BackgroundResultSingle CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells
He, X., Smeets, R. L., van Rijssen, E., Boots, A. M. H., Joosten, I., & Koenen, H. J. P. M. (2017) · Scientific Reports · doi:10.1038/srep43003 · Cited by 38
Dietary fatty acids and susceptibility to multiple sclerosis
Haase, S., Haghikia, A., Gold, R., & Linker, R. A. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517737372 · Cited by 41
Self-citationChung, D. C., Korn, T., Richard, J., Ruzek, M. C., Kohm, A. P., Miller, S., Nahill, S. R., & Oukka, M. (2007) · International Immunology · doi:10.1093/intimm/dxm078 · Cited by 38
“ries of pre-clinical models for autoimmune disease (28, 29 ) and transplantation (29) went into phase I clinical trial.”
BackgroundPrzybył, Ł., Ibrahim, T., Haase, N., Golić, M., Rugor, J., Luft, F. C., Bendix, I., Serdar, M., Wallukat, G., Staff, A. C., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04892 · Cited by 38
Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease
Beyersdorf, N., Ding, X., Hünig, T., & Kerkau, T. (2009) · Blood · doi:10.1182/blood-2009-04-218248 · Cited by 35
Self-citationThe Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 40
“This unfortunate event illustrates the fact that the balance between Treg and Teff cell responses in laboratory animals and humans and their response to superagonists can be significantly different (80, 83).”
BackgroundCan preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Shiao, S. L., McNiff, J. M., Masunaga, T., Tamura, K., Kubo, K., & Pober, J. S. (2007) · Transplantation · doi:10.1097/01.tp.0000251426.46312.d5 · Cited by 33
“In addition to blockade of CD28, there have been reports that suggest the agonistic effects of a CD28 antibody may also be paradoxically immunosuppressive through depletion of activated T cells (4) or, in the case of superagonists, selective activation of regulatory T cells (24).”
BackgroundImmune tolerance and control of CNS autoimmunity: from animal models to MS patients
Cassan, C., & Liblau, R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04270.x · Cited by 40
“Lastly, a high proliferation of Tregs in vivo, together with increased regulatory properties, has been achieved by treatment of rats with agonistic anti-CD28 monoclonal antibodies, thereby preventing and even treating EAE in these animals (Beyersdorf et al. 2005; Tischner et al. 2006).”
BackgroundZhu, Y., Li, J., Bai, Y., Wang, X., Duan, N., Jiang, H., Wang, T., & Wang, W. (2014) · Clinical Oral Investigations · doi:10.1007/s00784-013-1176-z · Cited by 33
Emerson, M. R., Gallagher, R. J., Marquis, J. G., & LeVine, S. M. (2009) · PubMed · Cited by 41
Humanized Mice, a New Model To Study the Influence of Drug Treatment on Neonatal Sepsis
Ernst, W., Zimara, N., Hanses, F., Männel, D. N., Seelbach-Göbel, B., & Wege, A. K. (2013) · Infection and Immunity · doi:10.1128/iai.01235-12 · Cited by 32
“The latest example is the agonistic monoclonal antibody TGN1412, which did not show critical side effects in mice (56, 57), whereas human volunteers receiving this antibody displayed respiratory distress, pulmonary infiltrates, cytokine storm, and lymphopenia (58).”
BackgroundCo-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?
Liu, W., Almo, S. C., & Zang, X. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1186690 · Cited by 34
“Conversely, administration of B7x-Ig proteins promoted the function and expansion of Tregs in the central nervous system (CNS) in an EAE mouse model (Podojil et al., 2013).”
BackgroundInfluentialSchmidt, T., Willenborg, S., Hünig, T., Deeg, C. A., Sønderstrup, G., Hertl, M., & Eming, R. (2015) · Experimental Dermatology · doi:10.1111/exd.12919 · Cited by 31
Foxp3+ Regulatory T Cells Control Persistence of Viral CNS Infection
Reuter, D., Sparwasser, T. D., Hünig, T., & Schneider‐Schaulies, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033989 · Cited by 30
Metadata
- Authors
- Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R.
- Affiliations
- University of Würzburg (DE)
- Universitätsklinikum Würzburg (DE)
- 3TeGenero ImmunoTherapeutics AG, D-97076 Würzburg, Germany
- 1Institute for Virology and Immunobiology, University of Würzburg
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2005-08-01
- Volume
- 202
- Issue
- 3
- Pages
- 445-455
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2213080
- OpenAlex
- W2150928170
- Cited by
- 203
- References
- 48
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 2 · 2018: 7 · 2017: 7 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 9 · 2012: 19
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Funders
- Bundesministerium für Bildung und Forschung
- Bayerische Forschungsstiftung
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- regulatory T cells, experimental autoimmune encephalomyelitis, multiple sclerosis, adoptive T cell therapy, Treg cell expansion, immunosuppression, myelin basic protein, autoimmune disease therapy, Lewis rats, Dark Agouti rats
- MeSH terms
- Animals, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Dose-Response Relationship, Immunologic, Encephalomyelitis, Autoimmune, Experimental, Immunosuppression Therapy, Injections, Intravenous, Lymphocyte Activation, Multiple Sclerosis, Rats, Inbred Lew, Receptors, Interleukin-2, CD4-Positive T-Lymphocytes, CD28 Antigens, Cell Proliferation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.